# Ocean Biomedical, Inc.: overview OCEA · OTC · CIK 1869974 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31 Pages: [Overview](/companies/ocea.md) · [Financials](/companies/ocea/financials.md) · [Filings](/companies/ocea/filings.md) · [Insiders](/companies/ocea/insiders.md) Revenue is not reported in this company’s XBRL financial statements. ## Last eight quarters | Line item | Unit | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $ | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Net margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Diluted EPS | $ per share | [(0.43)](/filings/0001493152-24-051208.md) | [(0.53)](/filings/0001493152-25-001880.md) | not reported | [0.48](/filings/0001641172-25-011080.md) | [(0.63)](/filings/0001493152-24-051208.md) | [(0.13)](/filings/0001641172-25-003155.md) | not reported | [(0.09)](/filings/0001641172-25-011080.md) | | Free cash flow | $ | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | - Revenue. XBRL not reported. - Gross margin (gross profit / revenue). XBRL not reported. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss. Derived values: 12-month figure less the 9-month figure. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss. Derived values: 12-month figure less the 9-month figure. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities. Derived values: 6-month figure less the 3-month figure; 9-month figure less the 6-month figure; 12-month figure less the 9-month figure. ## Last five fiscal years | Line item | Unit | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | | --- | --- | ---: | ---: | ---: | | Revenue | $ | not reported | not reported | not reported | | Gross margin | % | not reported | not reported | not reported | | Operating margin | % | not reported | not reported | not reported | | Net margin | % | not reported | not reported | not reported | | Diluted EPS | $ per share | [(0.74)](/filings/0001493152-24-047661.md) | [(4.35)](/filings/0001641172-25-003155.md) | [(0.34)](/filings/0001641172-25-003155.md) | | Free cash flow | $ | not reported | not reported | not reported | - Revenue. XBRL not reported. - Gross margin (gross profit / revenue). XBRL not reported. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/ocea/insiders.md) None in coverage. ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [FNY Investment Advisers, LLC](/funds/1742998.md) | 2026-06-30 | $0 | 600 | | Unchanged | ## Recent filings [All 255 filings](/companies/ocea/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2025-08-05 | 12:45 ET | [8-K](/filings/0001641172-25-022271.md) | 3.01 Delisting notice; 5.02 Departure or appointment of officers or directors; 8.01 Other events | 0001641172-25-022271 | | 2025-07-23 | 13:27 ET | [8-K](/filings/0001641172-25-020730.md) | 3.01 Delisting notice | 0001641172-25-020730 | | 2025-07-16 | 13:25 ET | [8-K](/filings/0001641172-25-019924.md) | 1.02 Termination of a material agreement | 0001641172-25-019924 | | 2025-06-13 | 13:25 ET | [8-K](/filings/0001641172-25-015129.md) | 1.02 Termination of a material agreement | 0001641172-25-015129 | | 2025-05-15 | 13:22 ET | [10-Q](/filings/0001641172-25-011080.md) | Quarterly report, period 2025-03-31 | 0001641172-25-011080 | | 2025-04-29 | 12:45 ET | [10-K/A](/filings/0001641172-25-006669.md) | Annual report, amended, period 2024-12-31 | 0001641172-25-006669 | | 2025-04-23 | 05:15 ET | [8-K](/filings/0001641172-25-005788.md) | 3.01 Delisting notice; 5.02 Departure or appointment of officers or directors; 8.01 Other events; 9.01 Financial statements and exhibits | 0001641172-25-005788 | | 2025-04-08 | 06:11 ET | [10-K](/filings/0001641172-25-003155.md) | Annual report, period 2024-12-31 | 0001641172-25-003155 | | 2025-04-01 | 12:05 ET | [8-K](/filings/0001641172-25-002074.md) | 5.07 Shareholder vote results | 0001641172-25-002074 | | 2025-03-26 | 12:10 ET | [8-K](/filings/0001641172-25-000747.md) | 8.01 Other events | 0001641172-25-000747 | ## Latest annual report [Form 10-K for the fiscal year ended Dec 31, 2024](/filings/0001641172-25-003155.md), filed Apr 8, 2025. ## Forecast league Not in this season’s league. [This season’s league](/leagues.md) ## About the filer - CIK: 1869974 - Tickers: OCEA - Exchange: OTC - SIC code: 2834 Pharmaceutical Preparations - State of incorporation: DE - Filer category:
Emerging growth company Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:49 ET. No prices; not investment advice.